The HLA locus and multiple sclerosis in Spain.: Role in disease susceptibility, clinical course and response to interferon-β

被引:55
作者
Villoslada, P
Barcellos, LF
Rio, J
Begovich, AB
Tintore, M
Sastre-Garriga, J
Baranzini, SE
Casquero, P
Hauser, SL
Montalban, X
Oksenberg, JR
机构
[1] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
[2] Hosp Gen Valle Hebron, Neuroimmunol Unit, Barcelona, Spain
[3] Roche Mol Syst Inc, Alameda, CA USA
[4] Childrens Hosp Oakland Res Inst, Oakland, CA USA
[5] Hosp Verge Toro, Neurol Unit, Mahon, Spain
关键词
multiple sclerosis; major histocompatibility complex; interferon; pharmacogenomics;
D O I
10.1016/S0165-5728(02)00215-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The HLA-DR2 haplotype (DRB1 * 1501, DQB1 * 0602) on chromosome 6p21 has consistently demonstrated both association and linkage with multiple sclerosis (MS) in case-control and family studies, particularly in Caucasians of Northern European descent. However, the role of a gene within this region in determining clinical features or response to immunotherapy remains largely unknown. A new familial MS data set from the Mediterranean Spanish Basin was collected according to rigorous ascertainment criteria. We confirm, primarily in the cohort originating from Continental Spain, that similar to other high-risk groups, there was a significant association with HLA-DR2. No other DR or DQ alleles were found to be associated with disease susceptibility nor were alleles at the class I A and B loci. Overall, the effect of HLA appears to be less substantial than that observed in a reference US population with a higher disease incidence. No effect of the HLA-DR2 haplotype on age of onset, initial clinical symptoms and disease course was observed. Similarly, no difference in the distribution of responders and nonresponders to interferon-beta (IFNB) therapy, as defined by primary and secondary end points, was observed when individuals were stratified according to HLA-DR2 status. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:194 / 201
页数:8
相关论文
共 48 条
[1]   ASSOCIATION OF SUSCEPTIBILITY TO MULTIPLE-SCLEROSIS IN SWEDEN WITH HLA CLASS-II DRB1 AND DQB1 ALLELES [J].
ALLEN, M ;
SANDBERGWOLLHEIM, M ;
SJOGREN, K ;
ERLICH, HA ;
PETTERSON, U ;
GYLLENSTEN, U .
HUMAN IMMUNOLOGY, 1994, 39 (01) :41-48
[2]  
Arnaiz-Villena A, 1999, HUM BIOL, V71, P725
[3]  
Barcellos LF, 2002, BRAIN, V125, P150
[4]  
BEGOVICH AB, 1992, J IMMUNOL, V148, P249
[5]  
Boon M, 2001, NEUROGENETICS, V3, P221
[6]   High-resolution analysis of human Y-chromosome variation shows a sharp discontinuity and limited gene flow between northwestern Africa and the Iberian Peninsula [J].
Bosch, E ;
Calafell, F ;
Comas, D ;
Oefner, PJ ;
Underhill, PA ;
Bertranpetit, J .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (04) :1019-1029
[7]   PREVALENCE OF MULTIPLE-SCLEROSIS IN THE REGION OF OSONA, CATALONIA, NORTHERN SPAIN [J].
BUFILL, E ;
BLESA, R ;
GALAN, I ;
DEAN, G .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1995, 58 (05) :577-581
[8]   DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians [J].
Caballero, A ;
Alvés-León, S ;
Papais-Alvarenga, R ;
Fernández, O ;
Navarro, G ;
Alonso, A .
TISSUE ANTIGENS, 1999, 54 (05) :524-526
[9]   Frequency of multiple sclerosis in Menorca, Balearic Islands, Spain [J].
Casquero, P ;
Villoslada, P ;
Montalbán, X ;
Torrent, M .
NEUROEPIDEMIOLOGY, 2001, 20 (02) :129-133
[10]   Recombinant human interferon beta in relapsing-remitting multiple sclerosis: a review of the major clinical trials [J].
Chofflon, M .
EUROPEAN JOURNAL OF NEUROLOGY, 2000, 7 (04) :369-380